Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
C4X Discovery Holdings PLC on Monday said it signed an exclusive worldwide licensing agreement with AstraZeneca PLC for its NRF2 Activator programme.
C4X Discovery shares were up 35% to 27.65 pence on Monday morning in London. AstraZeneca shares were down 0.4% at 10,914.00p.
C4X Discovery Holdings is a Manchester-based developer of drug discoveries.
The company said AstraZeneca will develop and commercialise an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic obstructive pulmonary disease.
The licensing agreement is worth up to $402 million, and C4X Discovery will receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront.
C4X Discovery said it is eligible to receive a further potential $385.8 million in clinical development and commercial milestones, and tiered mid-single digit royalties upon commercialisation.
‘Targeting the NRF2 pathway to reduce inflammatory damage offers the potential for a new approach to treat a variety of inflammatory diseases such as chronic obstructive pulmonary disease, where activation of NRF2 may help in reducing the negative effects of the oxidative stress-induced progression of the disease,’ C4XD Discovery Chief Executive Clive Dix said.
The agreement marks the third ‘significant deal’ for C4X Discovery with a major pharmaceutical company.
Copyright 2022 Alliance News Limited. All Rights Reserved.